Deruxtecan is an exatecan （Exa） derivative appended with a cleavable peptide linker.
It is a very potent inhibitor of topoisomerase I and an anticancer agent.
Deruxtecan is used to prepare antibody-drug conjugates （ADCs）, such as trastuzumab Deruxtecan （T-DXd, also known as Enhertu®, Daiichi Sankyo）, targeting HER2.
Deruxtecan is approved in HER2-expressing breast （BC） and gastric （GC） cancers.
This BSA-Deruxtecan conjugate is designed with the same linker chemistry as PDCs prepared using our Protein Deruxtecan Conjugation Kit （Cat#： CM11432）.
The BSA-Deruxtecan conjugate is synthesized at CellMosaic and has an average loading of 3 to 5 Deruxtecan molecules per BSA for immunization or immunoassay development.
The final conjugate is lyophilized from PBS containing sugar-based stabilizer for easy shipment and storage.The product is sold as either 1 vial of 1 mg （Cat# CM52140-1MG） or 5 vials of 1 mg （Cat# CM52140-5MG）.
